Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.

Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.

View in: PubMed

subject areas

Adrenal Cortex Hormones
Colitis, Ulcerative
Humans
Indans
Oxadiazoles
Remission Induction
Severity of Illness Index
Treatment Outcome

authors with profiles

David T. Rubin